Latent tuberculosis infection and interferon-gamma release assays: what new knowledge did we gain through the Journal in 2009?
|
|
- Miles Thomas
- 8 years ago
- Views:
Transcription
1 INT J TUBERC LUNG DIS 14(12): The Union 2009 YEAR IN REVIEW Latent tuberculosis infection and interferon-gamma release assays: what new knowledge did we gain through the Journal in 2009? M. J. van der Werf, F. van Leth Research Unit, KNCV Tuberculosis Foundation, The Hague, and Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands BOTH in vivo and in vitro tests are applied for the diagnosis of latent tuberculosis (TB) infection and for assessing the annual risk of infection in epidemiological studies. Both types of tests have their advantages and disadvantages. The 2009 issues of the International Journal of Tuberculosis and Lung Disease published studies that discuss tests for TB infection in different populations and for different purposes. Below we discuss these studies and relate them to other recent publications on the same topic. TUBERCULIN SKIN TEST SURVEYS Tuberculin skin test (TST) surveys are used for estimating the prevalence of infection and annual risk of tuberculosis infection (ARTI) in populations. The ARTI was used to estimate the incidence of sputum smear-positive TB applying the Styblo rule, 1 which assumed a fixed mathematical relationship between the incidence of smear-positive TB, the prevalence of smear-positive TB and the ARTI. This mathematical relationship is no longer considered to be valid. 2 Today, TST surveys are mainly considered useful for assessing time trends and geographical variations in risk of infection. 3 Three studies reported the results of TST surveys in schoolchildren. 4 6 Bachtiar et al. reported on single TST surveys in three provinces in Indonesia. The same authors reported on a similar study in another province in Indonesia in The absolute level of the ARTI reported in these studies is not very informative, as it highly depends on the analysis method chosen to estimate the prevalence of infection. 8,9 The studies did allow for a geographical comparison, with North Sulawesi having a higher ARTI (using mirror method with mode at 15 mm) than Central Java, East Nusa Tenggara or West Sumatra. Both publications from 2009 concluded that intensification of TB control efforts is needed in Indonesia to reduce the transmission of TB. 4,5 Al-Asbi et al. compared the results of a TST survey conducted in Yemen in 1991 with a tuberculin survey conducted in Their conclusion is that TB infection seems to be declining considerably. The 2007 survey results proved difficult to analyse and to interpret due to TST distributions without a clear mode or antimode. It is not possible to predict beforehand in which situation tuberculin surveys will give data that can be analysed and interpreted and in which situations this will prove to be difficult. A study in South Africa among gold miners determined the prevalence of latent TB infection (LTBI) using the TST, and assessed risk factors for a positive TST. 10 The prevalence of LTBI was very high in this population (89%). Factors independently associated with a TST < 10 mm were positive human immunodeficiency virus (HIV) status and not working underground. This study showed a clear frequency distribution of the indurations and a mode at 12 mm. In the analysis of the TST survey in Yemen, only non bacille Calmette-Guérin (BCG) vaccinated children were included. For the studies in Indonesia, the results of BCG-vaccinated and non-bcg-vaccinated children were reported separately and combined. In the Yemen study, 41% of the children had a BCG scar; in the three provinces in Indonesia, Nusa Tenggara, Central Java and North Sulawesi, respectively 52%, 87% and 79% had a BCG scar. The population-based TST survey among gold miners in South Africa reported that the distribution of TST responses was similar in BCG-vaccinated and non-vaccinated individuals, with 266 of 429 (62%) having a BCG scar. 10 In 2006, the results of an extensive literature review and meta-analysis assessing the effect of BCG vaccination on TST were reported in the Journal. 11 The authors concluded that the effect on TST of BCG received in infancy is minimal, especially 10 years or more after vaccination. However, BCG received after infancy produces more frequent, more persistent and larger TST reactions. As many countries will now have Correspondence to: Marieke J van der Werf, Unit Research, KNCV Tuberculosis Foundation, P O Box 146, The Hague 2501 CC, The Netherlands. Tel: (+31) Fax: (+31) vanderwerfm@kncvtbc.nl
2 1526 The International Journal of Tuberculosis and Lung Disease a BCG coverage of >80%, 12 the non-bcg-v accinated population will likely not be representative of the total study population. It seems prudent, therefore, to include BCG-vaccinated and non-bcg-vaccinated individuals in TST surveys and to assess whether there is a difference in the TST response, or to report TST positivity separately for BCG-vaccinated and non-vaccinated individuals, and to combine the two groups where possible. This is indeed what is done in the most recent surveys. 8,13 14 Another variable present in TST surveys is the type of tuberculin used. Sgountzos et al. showed that there was no difference between RT23 (Staten Serum Institute, Copenhagen, Denmark) and Merieux tuberculin (Mérieux Biological Institute, Lyons, France) when testing healthy police academy students in Athens. 15 Data comparing different tuberculin reagents are available from older studies These studies show varying results. The different tuberculin reagents may give comparable results or many discrepant results. The recommendation to use the same tuberculin in successive TST surveys thus still holds. 19 INDIRECT AND DIRECT MEASUREMENT OF ARTI TST surveys provide an indirect measurement of the ARTI. Del Rio Camacho et al. compared the indirect method used in TST surveys with a direct method of measuring ARTI, which is a formal incidence study. 20 For the direct method, schoolchildren with a negative TST result were retested 1 year after the initial test. The authors discuss the limited possibility of boosting, although they did not include BCG-vaccinated children. Of the following criteria that are used for considering a second TST to be positive 5 mm, >10 mm, 10 mm, or a difference of at least 6 mm or 12 mm with respect to the diameter of the preceding induration an increase of >10 mm between the first and second TST provided an ARTI that corresponded best to the ARTI obtained using the indirect method. IMMUNOSUPPRESSION AND TST Two studies used the TST for testing individuals with a risk factor for TB, i.e., diabetes and persons living with HIV/acquired immune-deficiency syndrome (PLWHAs). 21,22 Vitek et al. reported that 26% of PLWHAs tested in Orel Oblast in Russia had a positive TST result. This is a minimum prevalence, as HIV-infected individuals often lose TST sensitivity, which is predominantly attributable to anergy. 23 The authors recommend that the TB control programme in Russia implement TST screening among PLWHAs. Webb et al. tested children and adolescents with type 1 diabetes in the Western Cape Province in South Africa. 22 They report a high prevalence of TB disease (3488/ ), and recommend routine TB screening of children and adolescents in the Cape Province. INTERFERON-GAMMA RELEASE ASSAYS As there is no gold standard for TB infection, the evaluation of (new) diagnostic tests for TB infection remains a matter of controversy, although these tests are used in a wide variety of situations, including individual patient management, contact investigations and serial testing for individuals in high-risk settings for infection. Different settings will have different effects on the interpretation of the test results. This was shown in a study by O Neal et al., where a second generation interferon-gamma release assay (IGRA) was used in a contact investigation with proven TB transmission. 24 The authors rightly point out the negative predictive value of the test and its relationship with the assumed prevalence of TB infection in the study population, and conclude that the use of a QuantiFERON -TB (QFT) test in settings with a high pre-test risk of infection maybe suboptimal. Taking the assumed background prevalence of infection into account when interpreting test results is therefore recommended. A much debated issue around the use of IGRAs is the occurrence of conversions and reversions in the setting of serial testing, as was also included in a research agenda for T-cell-based assays published in 2007 by Pai et al. 25 Some of the questions were addressed in a study by Pai et al. concerning serial assessment of infection with the QuantiFERON -TB Gold (QFT-G) test in a household contact study. 26 It showed, not surprisingly, that the rate of conversion and reversion differed for different definitions of conversion and reversion. This needs to be taken into account when the tests are being used in community surveys where sample sizes are large and small differences between definitions are being amplified. QFT-G reversions were more likely when the QFT-G test at baseline was only weakly positive, giving rise to a change in test result when only minor changes around the QFT-G cut-off point take place. Such minor changes are quite possible given the substantial within-subject variation of the QFT-G test. In a systematic review, van Zyl-Smit et al. showed that this occurred in all three of the three studies included in the assessment, with a range of 16 80%. 27 Despite outstanding questions on the interpretation of QFT test results, the use of these tests was seen as cost-effective in a targeted screening intervention in individuals with a high risk of HIV infection in Mexico. Burgos et al. used a Markov Chain Monte Carlo modelling approach to assess the costs per LTBI case detected, TB case averted and quality-adjusted life year gained over a period of 20 years. 28 Input data were from intervention studies in the community. 29 In a related study, Garfein et al. describe the high
3 TST and IGRA: 2009 year in review 1527 prevalence of LTBI (67% by IGRA) among injection drug users. 30 This group of study participants is difficult to recruit for studies. If done, there is a high risk of a biased sample due to self-selection. The approach in this study was to use a respondent-driven sampling strategy. In this variant chain-referral method, initial recruits are given an incentive to participate and an additional incentive when they recruit others. This two-step incentive scheme is crucial to obtain a nonbiased study sample. 31 A prerequisite is that the community from which participants need to be recruited is closely connected. It is pleasing to see that newer methodology finds its way into TB research. However, the general reader must be able to assess the validity of these methods. It is therefore disappointing to see that the article does not give any insight into the success of the sampling, such as equilibrium estimates. COMPARISON OF TUBERCULIN SKIN TESTING AND INTERFERON-GAMMA RELEASE ASSAYS In 2009, several studies published in the Journal compared an IGRA with the TST. Comparison of the T- SPOT.TB assay (Oxford Immunotec, Abingdon, UK) with the TST in a TB low-prevalence area, the United States, in 326 individuals judged to have a low risk for TB infection showed excellent agreement between the two tests. 32 Overall agreement between the two tests was 98.2% (95% confidence interval [CI] ), and of the eight individuals with a positive T- SPOT.TB, six had a negative TST result. A study in a Canadian TB clinic analysed the QFT-G after implementation as a routine test for TST-positive patients. 33 QFT-G was used for all 1446 TST-positive ( 5 mm) individuals. Only 39.6% of the TST-positive patients were QFT-G-positive. The authors concluded that in this low-incidence country implementation of the QFT-G as a secondary test for LTBI can significantly reduce the number of patients given LTBI treatment. This assumes that QFT-G has superior test characteristics. The proposed strategy would be in accordance with the United Kingdom s National Institute of Health and Clinical Excellence recommendations. 34 In another low-incidence country, the Netherlands, the QuantiFERON -TB Gold In-Tube (QFT-GIT) test and the T-SPOT.TB were used to test immunocompetent individuals who were close contacts of sputum smear-positive TB patients and were born in a high TB endemic country, with a TST of 5 mm. 35 Of 282 individuals with valid outcomes (and thus TST 5 mm), the QFT-GIT was positive in 53.9% and the T-SPOT.TB was positive in 59.6%. The agreement between the TST (cut-off value 10 mm or 15 mm) and the two IGRAs was considered to be poor. An interesting finding was that a positive IGRA correlated well with possible recent TB infection, and with exposure to TB in the country of origin. A low degree of agreement between TST results and QFT results was also reported by Neal et al. during a contact investigation. 24 In a setting with proven TB transmission among co-workers of an infective TB patient, 18/61 (29.5%) co-workers had a TST > 5 mm but a negative QFT result, while 10 (16.4%) had a TST result > 15 mm and a negative QFT result. This indicates the poor sensitivity of the QFT test. As described earlier, a negative QFT is difficult to interpret when the background prevalence of infection is assumed to be high, as in this study. This might also have been the case in the study by Kik et al., 35 as in the Netherlands it has been shown that transmission of infection is markedly concentrated in similar social groups, making the background prevalence among contacts in the Dutch study rather high. 36 Shovman et al. compared the TST to the QFT-G in 35 patients with rheumatoid arthritis (RA) in Israel. 37 In this study population, overall agreement between the two tests was 56%, 45% had a TST > 5 mm, 11.4% had a positive QFT-G and the QFT-G was indeterminate in 10 (28.6%) RA patients. Ten RA patients tested TST-positive and QFT-negative, and one tested TST-negative and QFT-positive. The authors concluded that the clinical significance of a negative QFT-G in TST-positive patients with low TB risk remains to be assessed. Lew et al. used the QFT-G test to test TST-positive individuals ( 10 mm) in a contact investigation of a TB outbreak in South Korea. 38 Only 7.6% of the 388 TST-positive individuals were QFT-G-positive. The studies summarised above show that discordance between TST and QFT-G is frequent. A study in Brazil assessed what factors were associated with discordance. 39 In their study in household contacts of pulmonary TB patients, 61/255 (23.9%) contacts had discordant results, 44 were TST-positive and QFT- G-negative and 17 were TST-negative and QFT-Gpositive. Few factors were associated with discordance. Household contacts with a chest X-ray showing an old lung scar were more likely to have a positive TST test and a negative QFT-G, whereas household contacts with a reported length of exposure to the index case of >1 month were more likely to have a negative TST test and a positive QFT-G. A study of health care workers in Portugal showed that TST-positive/ QFT-negative discordance increased with the number of BCG vaccinations, and was more frequent in nurses compared to other professions. 40 Age >60 years was associated with increased TST-negative/QFT-positive discordance. Another study assessing factors associated with discordance among the general population examined in the scope of contact tracing and health care workers routinely screened for TB in Germany also identified BCG vaccination as a factor associated with TST-positive/QFT-negative discordance: in addition to this, being foreign-born was associated with discordance. 41 Davidow discusses the fact that assessing sensitivity
4 1528 The International Journal of Tuberculosis and Lung Disease and specificity for IGRAs uses substitute surrogate stand ins, as no gold standard for LTBI is available. 42 To assess sensitivity, subjects with active TB are tested, and to assess specificity subjects with an extremely low risk of TB infection are used. Using a mathematical model of LTBI test specificity, Davidow shows that the specificity of any test for LTBI is theoretically affected by its sensitivity to active TB, and by the distribution of TB, LTBI and healthy controls in the tested population. The author provides two solutions: 1) distinguishing LTBI suspects from TB suspects to correctly analyse data collected by field studies; and 2) assessing whether different cut-off points for IGRA use in TB suspects and LTBI suspects were needed. INTERFERON-GAMMA RELEASE ASSAYS FOR DIAGNOSIS OF NTM Some non-tuberculous mycobacteria (NTM), such as Mycobacterium kansasii, M. marinum, M. szulgai, M. flavescens and M. gastri, possess the M. tuberculosisspecific antigens early secreted antigenic target 6 (ESAT-6) and culture filtrate protein 10 (CFP-10). IGRAs may thus be able to assist in the diagnosis of NTMs other than M. avium-intracellulare complex (MAIC). Kobashi et al. evaluated the QuantiFERON TB-2G (QFT-2G) test in 214 patients with NTM disease that satisfied the diagnostic criteria of the American Thoracic Society. 43 The QFT-2G positivity rate was significantly lower in patients with MAIC disease compared to patients with diseases other than MAIC. The authors conclude that QFT-2G might be useful to differentiate TB from MAIC diseases. For diagnosing diseases other than MAIC, the best cutoff level for QFT-2G should be determined. ALTERNATIVE MARKERS FOR TUBERCULOSIS INFECTION Amidst the large number of studies reporting interferon-gamma (IFN-γ) as a marker for TB infection, attempts are being made to find alternative markers, among which the chemokine induced protein 10 (IP-10) has generated the most interest Lighter et al. describe a study from a setting with low prevalence of LTBI in which IP-10 was assessed as a marker for LTBI in children. 47 It showed that IP-10 production was not age-dependent, which gives it an advantage over IFN-γ in children. IP-10 production correlated well with the magnitude of exposure to TB, as was shown earlier. 48,49 As mentioned also by Ruhwald et al., a combination of an IGRA and assessment of IP-10 is likely to be more informative than either of these tests alone. 44 CONCLUSION The diagnosis of LTBI remains challenging without an objective gold standard. The well-known disadvantages of the conventional TST are just partly overcome by the newer IGRAs, resulting in a generally better sensitivity and specificity. However, the results of these tests should be interpreted with caution and take into account the expected prevalence of disease, and the possibilities of conversion and reversion of qualitative test results in serial testing. There is an urgent need for prospective studies that are welld esigned, both in size and duration, to assess the relationship between a positive IGRA test and the risk of developing active disease. The search for new diagnostics based on alternative markers of infection should continue. References 1 Styblo K. The relationship between the risk of tuberculous infection and the risk of developing infectious tuberculosis. Bull Int Union Tuberc 1985; 60: van Leth F, van der Werf M J, Borgdorff M W. Prevalence of tuberculous infection and incidence of tuberculosis: a rea ssessment of the Styblo rule. Bull World Health Organ 2008; 86: Dye C, Bassili A, Bierrenbach A L, et al. Measuring tuberculosis burden, trends, and the impact of control programmes. Lancet Infect Dis 2008; 8: Bachtiar A, Miko T Y, Machmud R, et al. Annual risks of tuberculous infection in East Nusa Tenggara and Central Java Provinces, Indonesia. Int J Tuberc Lung Dis 2009; 13: Bachtiar A, Miko T Y, Machmud R, et al. High risk of tuberculous infection in North Sulawesi Province of Indonesia. Int J Tuberc Lung Dis 2009; 13: Al-Absi A, Bassili A, Abdul Bary H, et al. The decline of tuberculosis in Yemen: evaluation based on two nationwide tuberculin surveys. Int J Tuberc Lung Dis 2009; 13: Bachtiar A, Miko T Y, Machmud R, et al. Annual risk of tuberculosis infection in West Sumatra Province, Indonesia. Int J Tuberc Lung Dis 2008; 12: Shanaube K, Sismanidis C, Ayles H, et al. Annual risk of tuberculous infection using different methods in communities with a high prevalence of TB and HIV in Zambia and South Africa. PLoS ONE 2009; 4: e Egwaga S M, Cobelens F G, Muwinge H, Verhage C, Kalisvaart N, Borgdorff M W. The impact of the HIV epidemic on tuberculosis transmission in Tanzania. AIDS 2006; 20: Hanifa Y, Grant A D, Lewis J, Corbett E L, Fielding K, Churchyard G. Prevalence of latent tuberculosis infection among gold miners in South Africa. Int J Tuberc Lung Dis 2009; 13: Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and nontuberculous mycobacteria? Int J Tuberc Lung Dis 2006; 10: World Health Organization. Immunization surveillance, assessment and monitoring. Geneva, Switzerland: WHO, summary/timeseries/tscoveragebcg.htm. Accessed August Addo K K, van den Hof S, Mensah G I, et al. A tuberculin skin test survey among Ghanaian school children. BMC Public Health 2010; 10: Kritzinger F E, den Boon S, Verver S, et al. No decrease in annual risk of tuberculosis infection in endemic area in Cape Town, South Africa. Trop Med Int Health 2009; 14: Sgountzos V, Simopoulou S, Kretsou S, et al. Comparative study of RT23 and Merieux tuberculin tested among healthy volunteers. Int J Tuberc Lung Dis 2009; 13:
5 TST and IGRA: 2009 year in review Blumberg H M, White N, Parrott P, Gordon W, Hunter M, Ray S. False-positive tuberculin skin test results among health care workers. JAMA 2000; 283: Villarino M E, Burman W, Wang Y C, et al. Comparable specificity of 2 commercial tuberculin reagents in persons at low risk for tuberculous infection. JAMA 1999; 281: Lifson A R, Watters J K, Thompson S, Crane C M, Wise F. Discrepancies in tuberculin skin test results with two commercial products in a population of intravenous drug users. J Infect Dis 1993; 168: Arnadottir T, Rieder H L, Trébucq A, Waaler H T. Guidelines for conducting tuberculin skin test surveys in high prevalence countries. Tubercle Lung Dis 1996; 77 (Suppl 1): S1 S del Río Camacho G, Perea-Milla E, Romero González J, Pérez Frías J. Interpretation of a serial Mantoux test taking into account the annual risk of tuberculous infection. Int J Tuberc Lung Dis 2009; 13: Vitek E, Gusseinova N, Laricheva N, et al. Factors associated with positive tuberculin skin test results among HIV-infected persons in Orel Oblast, Russia. Int J Tuberc Lung Dis 2009; 13: Webb E A, Hesseling A C, Schaaf H S, et al. High prevalence of Mycobacterium tuberculosis infection and disease in children and adolescents with type 1 diabetes mellitus. Int J Tuberc Lung Dis 2009; 13: Cobelens F G, Egwaga S M, van Ginkel T, Muwinge H, Matee M I, Borgdorff M W. Tuberculin skin testing in patients with HIV infection: limited benefit of reduced cutoff values. Clin Infect Dis 2006; 43: O Neal S, Hedberg K, Markum A, Schafer S. Discordant tuberculin skin and interferon-gamma tests during contact investigations: a dilemma for tuberculosis controllers. Int J Tuberc Lung Dis 2009; 13: Pai M, Dheda K, Cunningham J, Scano F, O Brien R. T-cell assays for the diagnosis of latent tuberculosis infection: moving the research agenda forward. Lancet Infect Dis 2007; 7: Pai M, Joshi R, Dogra S, et al. T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India. Int J Tuberc Lung Dis 2009; 13: van Zyl-Smit R N, Zwerling A, Dheda K, Pai M. Within-s ubject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review. PLoS ONE 2009; 4: e Burgos J L, Kahn J G, Strathdee S A, et al. Targeted screening and treatment for latent tuberculosis infection using Quanti- FERON -TB Gold is cost-effective in Mexico. Int J Tuberc Lung Dis 2009; 13: Garfein R S, Laniado-Laborin R, Rodwell T C, et al. Latent tuberculosis among persons at risk for infection with HIV, T ijuana, Mexico. Emerg Infect Dis 2010; 16: Garfein R S, Lozada R, Liu L, et al. High prevalence of latent tuberculosis infection among injection drug users in Tijuana, Mexico. Int J Tuberc Lung Dis 2009; 13: Heckathorn D D. Respondent-driven sampling: a new approach to the study of hidden populations. Social Problems 1997; 44: Bienek D R, Chang C K. Evaluation of an interferon-gamma release assay, T-SPOT.TB, in a population with a low prevalence of tuberculosis. Int J Tuberc Lung Dis 2009; 13: Kunimoto D, Der E, Beckon A, et al. Use of the QuantiFERON - TB Gold test to confirm latent tuberculosis infection in a Canadian tuberculosis clinic. Int J Tuberc Lung Dis 2009; 13: National Institute of Health and Clinical Excellence. Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London, UK: NICE, Accessed June Kik S V, Franken W P J, Arend S M, et al. Interferon-gamma release assays in immigrant contacts and effect of remote exposure to Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009; 13: Borgdorff M W, Nagelkerke N J, de Haas P E, van Soolingen D. Transmission of Mycobacterium tuberculosis depending on the age and sex of source cases. Am J Epidemiol 2001; 154: Shovman O, Anouk M, Vinnitsky N, et al. QuantiFERON -TB Gold in the identification of latent tuberculosis infection in rheumatoid arthritis: a pilot study. Int J Tuberc Lung Dis 2009; 13: Lew W J, Jung Y J, Song J-W, et al. Combined use of Quanti- FERON -TB Gold assay and chest computed tomography in a tuberculosis outbreak. Int J Tuberc Lung Dis 2009; 13: Machado A Jr, Finkmoore B, Emodi K, et al. Risk factors for failure to complete a course of latent tuberculosis infection treatment in Salvador, Brazil. Int J Tuberc Lung Dis 2009; 13: Torres Costa J, Sa R, Cardoso M J, et al. Tuberculosis screening in Portuguese healthcare workers using the tuberculin skin test and the interferon-gamma release assay. Eur Respir J 2009; 34: Nienhaus A, Schablon A, Diel R. Interferon-gamma release assay for the diagnosis of latent TB infection analysis of discordant results, when compared to the tuberculin skin test. PLoS ONE 2008; 3: e Davidow A L. Interferon-gamma release assay test characteristics depend upon the prevalence of active tuberculosis. Int J Tuberc Lung Dis 2009; 13: Kobashi Y, Mouri K, Yagi S, et al. Clinical evaluation of the QuantiFERON -TB Gold test in patients with non-tuberculous mycobacterial disease. Int J Tuberc Lung Dis 2009; 13: Ruhwald M, Ravn P. Biomarkers of latent TB infection. Expert Rev Respir Med 2009; 3: Ruhwald M, Bjerregaard-Andersen M, Rabna P, Eugen-Olsen J, Ravn P. IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA hold promise as biomarkers for infection with M. tuberculosis in a whole blood based T-cell assay. BMC Res Notes 2009; 2: Ruhwald M, Bodmer T, Maier C, et al. Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis. Eur Respir J 2008; 32: Lighter J, Rigaud M, Huie M, Peng C-H, Pollack H. Chemokine IP-10: an adjunct marker for latent tuberculosis infection in children. Int J Tuberc Lung Dis 2009; 13: Petrucci R, Abu Amer N, Gurgel R Q, et al. Interferon gamma, interferon-gamma-induced-protein 10, and tuberculin responses of children at high risk of tuberculosis infection. Pediatr Infect Dis J 2008; 27: Ruhwald M, Petersen J, Kofoed K, et al. Improving T-cell a ssays for the diagnosis of latent TB infection: potential of a diagnostic test based on IP-10. PLoS ONE 2008; 3: e2858.
Lisa Y. Armitige, MD, PhD has the following disclosures to make:
Interferon Gamma Release Assays (IGRAs) Lisa Y. Armitige, MD, PhD May 13, 2015 TB for Pulmonologist Phoenix, AZ March 13, 2015 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has the following
More informationCDC TB Testing Guidelines and Recent Literature Update
Pocket Guide QuantiFERON -TB Gold CDC TB Testing Guidelines and Recent Literature Update Using IGRAs for TB screening in your patients June 2010 A full copy of the US Centers for Disease Control and Prevention
More informationGuidelines for TB Blood Testing. Minnesota Department of Health TB Prevention and Control Program June 2011
Guidelines for TB Blood Testing Minnesota Department of Health TB Prevention and Control Program June 2011 Outline Interferon-Gamma Release Assays aka TB blood tests 1. What are they? 2. What are the current
More informationDRAFT FOR CONSULTATION
Interferon Gamma Release Assay (IGRA) testing for tuberculosis (TB) - Questions & Answers (Q&As) For Health Care Workers HPA Tuberculosis Programme Board DRAFT FOR CONSULTATION October 2007 Interferon
More informationWhat is an IGRA? What is an IGRA? Are they available here? How do I use them? Learning Objectives
What is an IGRA? Are they available here? How do I use them? Debbie Staley, RN, MPH TB Nurse Consultant VDH Division of Disease Prevention TB Control Program Learning Objectives Participants will be able
More informationT tuberculin Skin Test (TST) and QFT-GIT in Military Personnel
2 COMPARISON OF MANTOUX AND QUANTIFERON-TB GOLD TEST FOR DIAGNOSIS OF LATENT TUBERCULOSIS INFECTION IN ARMY PERSONNEL Willeke P.J. Franken 1, Joost F. Timmermans 2, Corine Prins 1, Evert-Jan H.J. Slootman
More informationHealth Protection Agency position statement on the use of Interferon Gamma Release Assay (IGRA) tests for Tuberculosis (TB)
Health Protection Agency position statement on the use of Interferon Gamma Release Assay (IGRA) tests for Tuberculosis (TB) Draft Interim HPA Guidance HPA Tuberculosis Programme Board Health Protection
More informationMassachusetts Department of Public Health Division of Global Populations and Infectious Disease Prevention
Massachusetts Department of Public Health Division of Global Populations and Infectious Disease Prevention Screening Infants and Children for Tuberculosis in Massachusetts Executive Summary In Massachusetts,
More informationHow To Test For Latent Tuberculosis
IGRAs: What do they tell and what don t they tell us? 2 nd European Advanced Clinical Tuberculosis Course Monday 22 nd September 2014 Amsterdam, Netherlands Ibrahim Abubakar Professor of Infectious Disease
More informationInterferon-gamma Release Assays: the Good, the Bad, and the Ugly
Interferon-gamma Release Assays: the Good, the Bad, and the Ugly Susan E. Dorman, MD Center for TB Research Johns Hopkins University School of Medicine Maryland Center for Tuberculosis Control and Prevention
More informationJournal of Infectious Diseases Advance Access published January 26, 2015
Journal of Infectious Diseases Advance Access published January 26, 2015 1 Effect of immune status on serial QuantiFERON-TB Gold In-Tube LTBI screening in persons with HIV in a low TB incidence country
More informationInterferon-gamma-release assays: Better than tuberculin skin testing?
REVIEW CME CREDIT EDUCATIONAL OBJECTIVE: Readers will use and interpret the new blood tests for tuberculosis correctly CYNDEE MIRANDA, MD Department of Infectious Disease, Medicine Institute, Cleveland
More informationPediatric Latent TB Diagnosis and Treatment
Date Updated: April 2015 Guidelines Reviewed: 1. CDC Latent TB Guidelines 2. Harborview Pediatric Clinic Latent TB Management, 2010 3. Pediatric Associates Latent TB Guidelines, 2013 4. Seattle Children
More informationNevada State Health Division Technical Bulletin
Nevada State Health Division Technical Bulletin Topic: Using QuantiFERON and Tuberculin Skin Test to Screen for TB Section/Program/Contact: Bureau of Community Health / Tuberculosis Program / Susanne Paulson,
More informationRole of Quantiferon-TB Gold Assays in Detecting Latent Tuberculous Infection among Contacts of Active Tuberculous Patients *
Med. J. Cairo Univ., Vol. 79, No. 1, June 169-175, 2011 www.medicaljournalofcairouniversity.com Role of Quantiferon-TB Gold Assays in Detecting Latent Tuberculous Infection among Contacts of Active Tuberculous
More informationChapter 3 Testing for Tuberculosis Infection and Disease
Chapter 3 Testing for Tuberculosis Infection and Disease Table of Contents Chapter Objectives.... 45 Introduction.... 47 Identifying High-Risk Groups for M. tuberculosis Testing... 47 Testing Methods for
More informationPerils and Pitfalls in Clinical Trials of Diagnostic Tests for Tuberculosis. Richard O Brien, MD Foundation for Innovative New Diagnostics Geneva
Perils and Pitfalls in Clinical Trials of Diagnostic Tests for Tuberculosis Richard O Brien, MD Foundation for Innovative New Diagnostics Geneva 1 Outline of Presentation Statement of the problem Common
More informationFrequently Asked Questions
Frequently Asked Questions QuantiFERON -TB Gold Health Professionals www.quantiferon.com 2 FAQ - Health Professionals Table of contents About TB 6 What is latent TB? And how is it different from active
More informationManaging Contacts. Challenges... 202. General Principles... 204. Summary of Options... 205. Variables to Consider... 205. Treatment Options...
10 Managing Contacts Challenges............ 202 General Principles...... 204 Summary of Options.... 205 Variables to Consider... 205 Treatment Options...... 206 Treatment of Children... 209 Window Prophylaxis....
More informationRisk for Tuberculosis in Swiss Hospitals. Content. Introduction. Dr. med. Alexander Turk Zürcher Höhenklinik Wald alexander.turk@zhw.
Risk for Tuberculosis in Swiss Hospitals 17. Tuberkulose Symposium Münchenwiler Risk for Tuberculosis in Swiss Hospitals Dr. med. Alexander Turk Zürcher Höhenklinik Wald alexander.turk@zhw.ch 1 Content
More informationTargeted Testing for Tuberculosis Infection
Targeted Testing for Tuberculosis Infection CONTENTS Introduction... 3.2 Purpose... 3.2 Policy... 3.2 When to Conduct Targeted Testing... 3.3 Approaches to increasing targeted testing and treatment for
More informationTuberculosis (TB) Screening Guidelines for Substance Use Disorder Treatment Programs in California
Tuberculosis (TB) Screening Guidelines for Substance Use Disorder Treatment Programs in California 1 of 7 Table of Contents Preface 2 TB Symptoms and TB History 2 Initial Screening 2 Follow-Up Screening
More informationTUBERCULOSIS SCREENING AND TREATMENT IN PREGNANCY. Stephanie N. Lin MD 2/12/2016
TUBERCULOSIS SCREENING AND TREATMENT IN PREGNANCY Stephanie N. Lin MD 2/12/2016 Epidemiology of TB 9.6 million new cases in 2014 12% of them are in HIV positive patients 1.5 million deaths in 2014 ~646
More information(In-Tube Method) The Whole Blood IFN-gamma Test Measuring Responses to ESAT-6, CFP-10 & TB7.7 Peptide Antigens PACKAGE INSERT
(In-Tube Method) The Whole Blood IFN-gamma Test Measuring Responses to ESAT-6, CFP-10 & TB7.7 Peptide Antigens PACKAGE INSERT For In Vitro Diagnostic Use BlanK Page INDEX 1. INTENDED USE 2 2. SUMMARY AND
More informationTUBERCULOSIS (TB) SCREENING GUIDELINES FOR RESIDENTIAL FACILITIES AND DRUG
TUBERCULOSIS (TB) SCREENING GUIDELINES FOR RESIDENTIAL FACILITIES AND DRUG Tx CENTERS Tuberculosis Control Program Health and Human Services Agency San Diego County INTRODUCTION Reducing TB disease requires
More informationDiagnosis of Tuberculosis Infection
Diagnosis of Tuberculosis Infection CONTENTS Introduction... 7.2 Purpose... 7.2 Policy... 7.2 High-Risk Groups... 7.3 Diagnosis of Tuberculosis Infection... 7.4 Interferon gamma release assays... 7.4 Mantoux
More informationAssisted Living - TB Risk Assessment
Montana DPHHS Tuberculosis Program Assisted Living - TB Risk Assessment Assisted Living, Adult Day Care, Adult Foster Care & Transitional Living Centers Today s Date Facility Address Phone County Completed
More informationSan Francisco Guidelines on the Use of QuantiFERON-TB Gold (In Tube Method) for the Diagnosis of Latent TB Infection
San Francisco Guidelines on the Use of QuantiFERON-TB Gold (In Tube Method) for the Diagnosis of Latent TB Infection Rationale When to Screen for TB Choosing the Right TB Test Patient Registration Pre-Test
More informationMaria Dalbey RN. BSN, MA, MBA March 17 th, 2015
Maria Dalbey RN. BSN, MA, MBA March 17 th, 2015 2 Objectives Participants will be able to : Understand the Pathogenesis of Tuberculosis (TB) Identify the Goals of Public Health for TB Identify Hierarchy
More informationPaediatrica Indonesiana. Limitations of the Indonesian Pediatric Tuberculosis Scoring System in the context of child contact investigation
Paediatrica Indonesiana VOLUME 51 November NUMBER 6 Original Article Limitations of the Indonesian Pediatric Tuberculosis Scoring System in the context of child contact investigation Rina Triasih 1,2,
More informationThe QuantiFERON-TB Gold test in the diagnosis and. treatment of latent tuberculosis in patients from a
The QuantiFERON-TB Gold test in the diagnosis and treatment of latent tuberculosis in patients from a Norwegian outpatient clinic Anne Margarita Dyrhol-Riise 1, Gerd Gran 2, Tore Wenzel Larsen 3, Bjørn
More informationSerial Testing of Refugees for Latent Tuberculosis Using the QuantiFERON-Gold In-Tube: Effects of an Antecedent Tuberculin Skin Test
Am. J. Trop. Med. Hyg., 80(4), 2009, pp. 628 633 Copyright 2009 by The American Society of Tropical Medicine and Hygiene Serial Testing of Refugees for Latent Tuberculosis Using the QuantiFERON-Gold In-Tube:
More informationInterferon Gamma Release Assays (IGRAs) in the Diagnosis of Tuberculosis
Interferon Gamma Release Assays (IGRAs) in the Diagnosis of Tuberculosis Richard B. Clark, PhD, D(ABMM) Quest Diagnostics Nichols Institute Chantilly, VA Dale Schwab, PhD, D(ABMM) Quest Diagnostics Nichols
More informationAn Evaluation of QuantiFERON-TB Gold In-Tube and Immunological Tests for TB Diagnosis in Iraqi Patients
An Evaluation of QuantiFERON-TB Gold In-Tube and Immunological Tests for TB Diagnosis in Iraqi Patients Mohemid M. Al-Jebouri 1 and Nuha M. Wahid 2 1 Department of Microbiology, College of Medicine, University
More informationSerial Testing for TB Infection with IGRAs: Understanding the Sources of Variability
Serial Testing for TB Infection with IGRAs: Understanding the Sources of Variability Niaz Banaei MD Assistant Professor of Pathology and Medicine Director, Fellowship in Global Health Diagnostics Director,
More informationGuidelines for Tuberculosis Control in New Zealand 2010 Chapter 8: Diagnosis and Treatment of Latent Tuberculosis Infection
Guidelines for Tuberculosis Control in New Zealand 2010 Chapter 8: Diagnosis and Treatment of Latent Tuberculosis Infection Ministry of Health. 2010. Guidelines for Tuberculosis Control in New Zealand
More informationRecent Advances in The Treatment of Mycobacterium Tuberculosis
Recent Advances in The Treatment of Mycobacterium Tuberculosis Dr Mohd Arif Mohd Zim Senior Lecturer & Respiratory Physician Faculty of Medicine, Universiti Teknologi MARA mohdarif035@salam.uitm.edu.my
More informationSPECIAL FEATURES: HEALTH POLICY
Public Health Nursing 0737-1209/ 2013 Wiley Periodicals, Inc. doi: 10.1111/phn.12083 SPECIAL FEATURES: HEALTH POLICY Cost-effectiveness of Using Quantiferon Gold (QFT-G) versus Tuberculin Skin Test (TST)
More informationFor reprint orders, please contact reprints@future-drugs.com. Diagnosis of latent. Expert Rev. Anti Infect. Ther. 3(6), 981 993 (2005)
Review For reprint orders, please contact reprints@future-drugs.com Diagnosis of latent Mycobacterium tuberculosis infection: is the demise of the Mantoux test imminent? James S Rothel and Peter Andersen
More informationUpdated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis Infection United States, 2010
Morbidity and Mortality Weekly Report www.cdc.gov/mmwr Recommendations and Reports June 25, 2010 / Vol. 59 / No. RR-5 Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium
More informationTuberculosis Contact Investigation in a Renal Dialysis Center: Blood Vs. Skin test
Tuberculosis Contact Investigation in a Renal Dialysis Center: Blood Vs. Skin test Kevin L. Winthrop M.D., M.P.H. Assistant Professor of Medicine Divisions of Infectious Diseases and Public Health and
More informationChildhood Tuberculosis Some Basic Issues. Jeffrey R. Starke, M.D. Baylor College of Medicine
Childhood Tuberculosis Some Basic Issues Jeffrey R. Starke, M.D. Baylor College of Medicine TUBERCULOSIS IS A SOCIAL DISEASE WITH MEDICAL IMPLICATIONS THE GREAT PARADOX OF TUBERCULOSIS A CAUTIONARY TALE
More informationChapter 1 Overview of Tuberculosis Epidemiology in the United States
Chapter 1 Overview of Tuberculosis Epidemiology in the United States Table of Contents Chapter Objectives.... 1 Progress Toward TB Elimination in the United States.... 3 TB Disease Trends in the United
More informationRole of QuantiFERON-TB Gold In-Tube test in detection of latent tuberculosis infection in health care contacts in Alexandria, Egypt
Vol. 8(12), pp. 1310-1317, 19 March, 2014 DOI: 10.5897/AJMR2013.6502 ISSN 1996-0808 Copyright 2014 Author(s) retain the copyright of this article http://www.academicjournals.org/ajmr African Journal of
More informationPregnancy and Tuberculosis. Information for clinicians
Pregnancy and Tuberculosis Information for clinicians When to suspect Tuberculosis (TB)? Who is at risk of TB during pregnancy? Recent research suggests that new mothers are at an increased risk of TB
More informationPolicy Directive: compliance is mandatory
Policy Directive: compliance is mandatory Policy for Control of Tuberculosis in South Australian Health Services Policy developed by: Public Health and Clinical Coordination Approved at Portfolio Executive
More informationInterferon-gamma release assays and childhood tuberculosis: systematic review and meta-analysis
INT J TUBERC LUNG DIS e-publication ahead of print 8 June 2011 2011 The Union doi:10.5588/ijtld.10.0631 REVIEW ARTICLE Interferon-gamma release assays and childhood tuberculosis: systematic review and
More informationSanta Clara County Tuberculosis Screening Requirement for School Entrance Effective June 1, 2014. Frequently Asked Questions
Frequently Asked Questions A child has history of BCG vaccination, should they have TST or IGRA? According to the American Academy of Pediatrics Red Book (2012), Interferon Gamma Release Assay (IGRA) is
More informationNo influence of haemodialysis on interferon production in the QuantiFERON-TB Gold-In-Tube test
ORIGINAL ARTICLE JN EPHROL 24( 2011; 05) : 625-630 DOI:10.5301/JN.2011.6325 No influence of haemodialysis on interferon production in the QuantiFERON-TB Gold-In-Tube test Martine Hoogewerf 1, Greet J.
More informationALTERNATIVES TO THE TUBERCULIN SKIN TEST: INTERFERON-γ ASSAYS IN THE DIAGNOSIS OF MYCOBACTERIUM TUBERCULOSIS INFECTION
Indian Journal of Medical Microbiology, (2005) 23 (3):151-158 Review Article ALTERNATIVES TO THE TUBERCULIN SKIN TEST: INTERFERON-γ ASSAYS IN THE DIAGNOSIS OF MYCOBACTERIUM TUBERCULOSIS INFECTION M Pai
More informationDIVISION of SUBSTANCE ABUSE SERVICES. Tuberculosis Control Guidelines for Alcohol and Drug Abuse Treatment Programs
DIVISION of SUBSTANCE ABUSE SERVICES Tuberculosis Control Guidelines for Alcohol and Drug Abuse Treatment Programs 1. Purpose: This policy provides guidance and instruction to identify and prevent tuberculosis
More informationTuberculosis. Subject. Goal/Objective. Instructions. Rationale. Operations Directorate, Health Branch Immigration Medical Examination Instructions
Subject Instructions for the screening of clients to detect tuberculosis (TB) in the context of the Canadian immigration medical examination (IME). Goal/Objective These instructions are provided to ensure
More informationTuberculosis Surveillance and Screening for Long Term Care Facilities in Colorado
Tuberculosis Surveillance and Screening for Long Term Care Facilities in Colorado Developed by the Colorado Medical Directors Association and The Colorado Department of Public Health and Environment Introduction:
More informationInterferon-gamma release assays during follow-up of tuberculin skin test-positive contacts
INT J TUBERC LUNG DIS 12(11):1286 1294 2008 The Union Interferon-gamma release assays during follow-up of tuberculin skin test-positive contacts W. P. J. Franken,* S. M. Arend,* S. F. T. Thijsen, J. J.
More informationOriginally published as:
Originally published as: Reuss, A.M., Wiese-Posselt, M., Weißmann, B., Siedler, A., Zuschneid, I., An Der Heiden, M., Claus, H., Von Kries, R., Haas, W.H. Incidence rate of nontuberculous mycobacterial
More informationTuberculosis infection in drug users: interferon-gamma release assay performance
INT J TUBERC LUNG DIS 11(11):1183 1189 2007 The Union Tuberculosis infection in drug users: interferon-gamma release assay performance C. Z. Grimes,* L-Y. Hwang,* M. L. Williams,* C. M. Austin, E. A. Graviss
More informationTable. Positive Purified Protein Derivative Results (Pediatrics In Review Apr 2008)
PPD and TB Sreening COMPETENCY- The resident should know the risk factors for TB exposure, when to screen, and the appropriate criteria for recognizing a positive PPD in children of different age groups
More informationSummary. Request for Advice
Summary Health Council of the Netherlands. Vaccination of young children against tuberculosis. The Hague: Health Council of the Netherlands, 2011; publication no. 2011/04 Even though the global prevalence
More informationATTACHMENT 2. New Jersey Department of Health Tuberculosis Program FREQUENTLY ASKED QUESTIONS
ATTACHMENT 2 New Jersey Department of Health Tuberculosis Program FREQUENTLY ASKED QUESTIONS 1. QUESTION Is it required to submit the Annual Report of TB Testing in Schools Form (TB-57) to the New Jersey
More informationCanadian Tuberculosis Standards
Canadian Tuberculosis Standards 7 th Edition Chapter 4: Diagnosis of Latent Tuberculosis Infection Canadian Tuberculosis Standards, 7 th Edition is available on Internet at the following address: www.phac-aspc.gc.ca
More informationTuberculosis Exposure Control Plan for Low Risk Dental Offices
Tuberculosis Exposure Control Plan for Low Risk Dental Offices A. BACKGROUND According to the CDC, approximately one-third of the world s population, almost two billion people, are infected with tuberculosis.
More informationAmerican College Health Association (ACHA) TB Screening and Targeted Testing Recommendations Gregory Juckett, MD, MPH Professor of Family Medicine
American College Health Association (ACHA) TB Screening and Targeted Testing Recommendations Gregory Juckett, MD, MPH Professor of Family Medicine West Virginia University gjuckett@hsc.wvu.edu Objectives
More informationLong-term Care - TB Risk Assessment
Montana DPHHS Tuberculosis Program Long-term Care - TB Risk Assessment Long-term Care, Residential Treatment, ESRD (outpatient), Hospice (inpatient) Today s Date Facility Address Phone County Completed
More informationTuberculosis in children in Europe -the ptbnet
Tuberculosis in children in Europe -the ptbnet Beate Kampmann FRCPCH PhD A/Professor in Paediatric Infection & Immunity Consultant Paediatrician Imperial College London, UK and Institute of Infectious
More informationCTCA POSITION ON TB EXAMINATION OF SCHOOL EMPLOYEES AND VOLUNTEERS
CTCA POSITION ON TB EXAMINATION OF SCHOOL EMPLOYEES AND VOLUNTEERS Introduction Although progress has been made, tuberculosis (TB) continues to be a significant public health problem; appropriate TB examination
More informationAlcohol abuse and smoking
Alcohol abuse and smoking Important risk factors for TB? 18 th Swiss Symposium on tuberculosis Swiss Lung Association 26 Mach 2009 Knut Lönnroth Stop TB Department WHO, Geneva Full implementation of Global
More information3. Blood and blood products such as serum, plasma, and other blood components.
Mississippi Downloaded 01/2011 101.11 Infectious Medical Waste. The term "infectious medical waste" includes solid or liquid wastes which may contain pathogens with sufficient virulence and quantity such
More informationTuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges
Tuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges John B. Kaneene, DVM, MPH, PhD University Distinguished Professor of Epidemiology Director, Center for Comparative Epidemiology
More informationClinical description 2 Laboratory test for diagnosis 3. Incubation period 4 Mode of transmission 4 Period of communicability 4
Tuberculosis Contents Epidemiology in New Zealand 2 Case definition 2 Clinical description 2 Laboratory test for diagnosis 3 Case classification 3 Spread of infection 4 Incubation period 4 Mode of transmission
More informationResearch Article Tuberculin Skin Tests versus Interferon-Gamma Release Assays in Tuberculosis Screening among Immigrant Visa Applicants
Tuberculosis Research and Treatment, Article ID 217969, 11 pages http://dx.doi.org/10.1155/2014/217969 Research Article Tuberculin Skin Tests versus Interferon-Gamma Release Assays in Tuberculosis Screening
More informationTargeted Testing and Treatment of Latent Tuberculosis Infection in Adults and Children
C D H S / C T C A J O I N T G U I D E L I N E S Targeted Testing and Treatment of Latent Tuberculosis Infection in Adults and Children Targeted Skin Testing and Treatment of Latent Tuberculosis Infection
More informationPEOSH Model Tuberculosis Infection Control Program
PEOSH Model Tuberculosis Infection Control Program Revised November, 2004 NOTE: The information in this document is not considered to be a substitute for any provision of the PEOSH Act or for any standards
More informationPromise versus reality - Optimism bias in package inserts of TB diagnostics
Promise versus reality - Optimism bias in package inserts of TB diagnostics Claudia Denkinger, MD PhD Beth Israel Deaconess Medical Center, Boston McGill University, Montreal cdenking@bidmc.harvard.edu
More informationMycobacterium bovis infection in a young Dutch adult: transmission from an elderly human source?
3B Mycobacterium bovis infection in a young Dutch adult: transmission from an elderly human source? OW Akkerman K van der Loo D Nijmeijer T van der Werf B Mulder K Kremer D van Soolingen AGM van der Zanden
More informationApril 22, 2015 Curry International Tuberculosis Center
Tools for TB Elimination: Early Case Finding and Prevention Determining Your High-Risk Groups: Using the Universal Risk Assessment Tool Wednesday, d Sacramento, California Mike Carson, MS Program Manager
More informationMaryland County Health Department Tuberculosis Infection Control Plan
Maryland County Health Department Tuberculosis Infection Control Plan Introduction In 1998, the Division of TB Control developed a Tuberculosis (TB) Prevention Plan template for use by the local health
More informationGuidelines on targeted tuberculin testing and treatment of latent tuberculosis infection
Guidelines on targeted tuberculin testing and treatment of latent tuberculosis infection Tuberculosis and Chest Service (Last update on 31March 2015) Internal guidelines of the Tuberculosis & Chest Service
More informationComparison of Quantiferon-TB Gold versus Tuberculin Skin Test for Tuberculosis Screening in Inflammatory Bowel Disease Patients
Comparison of Quantiferon-TB Gold versus Tuberculin Skin Test for Tuberculosis Screening in Inflammatory Bowel Disease Patients Gianluca Andrisani, Alessandro Armuzzi, Alfredo Papa, Manuela Marzo, Carla
More informationFaculty of Public Health
Faculty of Public Health Of the Royal Colleges of Physicians of the United Kingdom Working to improve the public s health OSPHE 075 Contact Investigations for TB Contact Investigations for TB CANDIDATE
More informationECDC GUIDANCE. Management of contacts of MDR TB and XDR TB patients. www.ecdc.europa.eu
Management of contacts of MDR TB and XDR TB patients www.ecdc.europa.eu Management of contacts of MDR TB and XDR TB patients The content of this guidance was developed by the European Centre for Disease
More informationAssessing patients for infection with Mycobacterium tuberculosis
ORIGINAL STUDIES The Likelihood of an Indeterminate Test Result from a Whole-Blood Interferon- Release Assay for the Diagnosis of Mycobacterium tuberculosis Infection in Children Correlates With Age and
More informationThe Cost Effectiveness of Interferon Gamma Release Assays Versus Tuberculin Skin Tests in Health Care
ORIGINAL INVESTIGATION Cost-effectiveness of Interferon Gamma Release Assays vs Tuberculin Skin Tests in Health Care Workers Marie A. de Perio, MD; Joel Tsevat, MD, MPH; Gary A. Roselle, MD; Stephen M.
More informationSelf-Study Modules on Tuberculosis
Self-Study Modules on Tuberculosis Epidemiology of Tuberculosis U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Center for HIV/AIDS, Viral Hepatitis, STD,
More informationWhat You Need to Know About Collecting QuantiFERON (QFT) TB Gold In-Tube Samples
What You Need to Know About Collecting QuantiFERON (QFT) TB Gold In-Tube Samples I. What is QuantiFERON (QFT) TB Gold In-Tube? II. III. QFT is an interferon-gamma release assay (IGRA). QFT is a blood test.
More informationDaniel Chemtob MD MPH DEA 1,2, Daniel Weiler-Ravell MD 1,2, Alex Leventhal MD MPH MPA 2 and Haim Bibi MD 3. Patients and Methods Case studies
Epidemiologic Characteristics of Pediatric Active Tuberculosis Among Immigrants from High to Low Tuberculosis-Endemic Countries: the Israeli Experience* Daniel Chemtob MD MPH DEA 1,2, Daniel Weiler-Ravell
More informationScreening and preventive therapy for MDR/XDR-TB exposed/infected children (and adults)
Screening and preventive therapy for MDR/XDR-TB exposed/infected children (and adults) H S Schaaf Department of Paediatrics and Child Health, and Desmond Tutu TB Centre Stellenbosch University, and Tygerberg
More information09/27/2006 Centers for Disease Control and Prevention Division of Tuberculosis Elimination
Appendix B. Tuberculosis (TB) risk assessment worksheet This model worksheet should be considered for use in performing TB risk assessments for healthcare facilities and nontraditional facility-based settings.
More informationTB Diagnostics: looking back and looking forward
TB Diagnostics: looking back and looking forward Raul V. Destura MD Institute of Molecular Biology and Biotechnology National Institutes of Health University of the Philippines, Manila Disturbing Statistics
More informationAge In London TB is more common in younger adults aged 15-44 years and peaks in the 25-34 age group (3).
4. TUBERCULOSIS INTRODUCTION Tuberculosis (TB) is an infectious, notifiable disease (meaning there is a requirement by law to report it to government authorities) caused by the bacterium Mycobacterium
More informationTB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 TB in the HIV Patient Lisa Armitige, MD, PhD November 13, 2014 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests
More informationUse of Interferon Gamma Release Assays as Confirmatory Test for Tuberculin Skin Test-Positive Patients in the Canadian Armed Forces
Use of Interferon Gamma Release Assays as Confirmatory Test for Tuberculin Skin Test-Positive Patients in the Canadian Armed Forces Milan Patel Surgeon General Report Surgeon General Health Research Program
More informationTB preventive therapy in children. Introduction
TB preventive therapy in children H S Schaaf Department of Paediatrics and Child Health, and Desmond Tutu TB Centre Stellenbosch University, and Tygerberg Children s Hospital Introduction Children are
More informationDepartment of Internal Medicine, Division of Cardiovascular Diseases. Department of Internal Medicine. Department of Internal Medicine
Use of the QuantiFERON -TB Gold Assay in Pregnant Patients Bassem M.Chehab, M.D. 1, K. James Kallail, Ph.D. 2, Riad O. El Fakih, M.D. 3, Rosalee E. Zackula, M.A. 4, Garold O. Minns, M.D. 2 1 University
More informationFrequently Asked Questions
Frequently Asked Questions QuantiFERON-TB Gold Health Professionals www.quantiferon.com Table of contents About TB 4 What is latent TB? And how is it different to active TB disease? 4 What is the meaning
More informationTuberculin Skin Testing
Document Number PD2009_005 Publication date 30-Jan-2009 Tuberculin Skin Testing Functional Sub group Clinical/ Patient Services - Infectious diseases Clinical/ Patient Services - Medical Treatment Population
More informationHow To Calculate The Incidence Of Mycobacterium Tuberculosis
Burden of childhood tuberculosis in 22 high-burden countries: a mathematical modelling study Peter J Dodd, Elizabeth Gardiner, Renia Coghlan, James A Seddon Summary Background Confirmation of a diagnosis
More informationYou can get more information about TB from the following: Local Public Health Nurse Community Clinic Nurse Communicable Disease Control Nurse Your Family or Community Doctor Your Infection Control Practitioner
More informationTuberculosis Prevention and Control Protocol, 2008
Tuberculosis Prevention and Control Protocol, 2008 Preamble The Ontario Public Health Standards (OPHS) are published by the Minister of Health and Long- Term Care under the authority of the Health Protection
More informationPathologie Biologie 57 (2009) e49 e53. Original article
Pathologie Biologie 57 (2009) e49 e53 Original article IFNg and antibody responses among French nurses during a tuberculosis contact tracing investigation Réponse IFNg et anticorps parmi les personnels
More informationGuidelines for Tuberculosis Screening of Healthcare Students in the greater Auckland region
Guidelines for Tuberculosis Screening of Healthcare Students in the greater Auckland region Auckland Regional Public Health Service 2013 Document Controller: Updated December 2013 Medical Officer of Health,
More information